The U.S. Food and Drug Administration (FDA) has approved Hovilpri™ (pritelivir), a new oral antiviral medication for adults with weakened immune systems who have herpes simplex virus (HSV) infections that have not responded to standard treatments.

The approval offers another treatment option for patients who experience persistent, painful sores caused by HSV, particularly when commonly prescribed antiviral medications have been ineffective.

What Is Herpes Simplex Virus?

Herpes simplex virus is a common infection caused by two types of viruses, HSV-1 and HSV-2. Both can cause painful blisters or sores on the skin and mucous membranes, including areas around the mouth and genitals.

Once someone becomes infected, the virus remains in the body for life. Although antiviral medications can help manage outbreaks, there is currently no cure for HSV.

People with weakened immune systems, including those living with HIV, receiving cancer treatment, or recovering from organ transplants, may experience more frequent or severe outbreaks. In some cases, infections do not improve with standard antiviral medications.

How Does Hovilpri Work?

Hovilpri contains pritelivir, an antiviral medication that works differently from commonly used HSV treatments such as acyclovir, valacyclovir, and famciclovir.

The medication blocks a group of viral proteins called the helicase-primase complex, which HSV needs to copy its genetic material and reproduce.

By interfering with this process, Hovilpri helps prevent the virus from multiplying, allowing existing sores to heal.

Hovilpri is taken by mouth, beginning with a higher dose on the first day, followed by a once-daily dose until the lesions have healed.

What Did Clinical Trials Find?

The FDA’s approval was supported by results from a Phase 3 clinical trial involving 101 adults with weakened immune systems whose HSV infections had not responded to standard antiviral medications.

Participants received either Hovilpri or another treatment selected by the study investigator.

After 28 days, 63% of patients receiving Hovilpri had complete healing of their HSV lesions, compared with 34% of patients receiving other treatments.

Treatment could continue for up to 42 days if patients showed improvement but their lesions had not completely healed.

These findings suggest that Hovilpri may provide an effective treatment option for patients with persistent HSV infections that are difficult to manage with existing medications.

What Are the Side Effects?

The most commonly reported side effect of Hovilpri was headache, which occurred in approximately 6% of patients receiving the medication during the Phase 3 trial.

Hovilpri can also interact with certain medications, particularly those used to reduce stomach acid. Some of these medications may interfere with how well Hovilpri is absorbed, potentially reducing its effectiveness.

Patients should inform their healthcare providers about all medications they are taking before beginning treatment.

What Does This Approval Mean for Patients?

The approval of Hovilpri provides an additional treatment option for adults with weakened immune systems who have HSV sores that do not respond to commonly prescribed antiviral medications.

Its different mechanism of action may be particularly valuable when existing treatments are ineffective.

However, Hovilpri does not cure herpes simplex virus or eliminate the infection from the body. Its FDA approval is specifically for treating difficult-to-treat HSV lesions in adults with weakened immune systems, not for routine herpes outbreaks in otherwise healthy individuals.

The approval represents an important development for patients who have limited treatment options for persistent HSV infections.

Sources

  1. U.S. Food and Drug Administration. FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus. October 9, 2026. Accessed by: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-lesions-caused-herpes-simplex-virus
  2. U.S. Food and Drug Administration. Hovilpri (pritelivir) tablets, for oral use. Prescribing Information. Revised October 2026. Accessed by: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/221154Orig1s000lbl.pdf

You May Also Like